
Soligenix Inc. Advances in Treating Severe Oral Mucositis with SGX942
Soligenix Inc. is making strides with SGX942, a novel treatment for severe oral mucositis, showing promising phase 3 results in reducing the condition's severity and duration in head and neck cancer patients.
Read full story





















